CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
548 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
GSK3-IN-10
CAS :GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Formule :C17H18F2N4O3Couleur et forme :SolidMasse moléculaire :364.347CDK4/6-IN-13
CAS :Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.Formule :C25H29N7OCouleur et forme :SolidMasse moléculaire :443.54Anticancer agent 29
Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).Formule :C22H15ClFNOCouleur et forme :SolidMasse moléculaire :363.81Cdc7-IN-18
CAS :Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).Formule :C19H21N5OSCouleur et forme :SolidMasse moléculaire :367.47Protein kinase inhibitor 11
CAS :Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.Formule :C21H18FN5O2SCouleur et forme :SolidMasse moléculaire :423.463CTX-712
CAS :CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.Formule :C19H17FN8O2Couleur et forme :SolidMasse moléculaire :408.39CDK9-IN-38
CAS :CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.Formule :C22H23N5O3SCouleur et forme :SolidMasse moléculaire :437.515Cdc7-IN-19
CAS :Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].Formule :C19H21N5O2Couleur et forme :SolidMasse moléculaire :351.40PKMYT1-IN-7
CAS :PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.Formule :C17H18FN5O3Couleur et forme :SolidMasse moléculaire :359.355CDK4-IN-1
CAS :CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50Formule :C22H29ClN8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.97P162-0948
CAS :P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.Formule :C20H15FN4O2Couleur et forme :SolidMasse moléculaire :362.357CDK4/9-IN-1
CAS :CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.Formule :C22H34N6O2Couleur et forme :SolidMasse moléculaire :414.544CDK2-IN-39
CAS :CDK2-IN-39 (compound 4) is a CDK2 inhibitor.Formule :C14H15N3O4SCouleur et forme :SolidMasse moléculaire :321.352CDK2-IN-40
CAS :CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.Formule :C16H21N7O2Couleur et forme :SolidMasse moléculaire :343.384Zeltociclib
CAS :Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.Formule :C18H20F3N4O2PCouleur et forme :SolidMasse moléculaire :412.346CDK4/6-IN-24
CAS :CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.Formule :C32H41N7O3Couleur et forme :SolidMasse moléculaire :571.713CDK7-IN-31
CAS :CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.Formule :C27H32F5N6O2PCouleur et forme :SolidMasse moléculaire :598.55(R)-Atuveciclib
CAS :Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].Formule :C18H18FN5O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :387.43TMX-3013
CAS :TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.Formule :C17H14BrFN6O3SCouleur et forme :SolidMasse moléculaire :481.3LZ9
CAS :LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.Formule :C17H11F3N4O2Couleur et forme :SolidMasse moléculaire :360.29CDK1-IN-6
CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.Formule :C21H22N4OCouleur et forme :SolidMasse moléculaire :346.43CDK2 degrader 4
CAS :CDK2 degrader4 (compound 104) is a potent degrader of CDK2, showing promise for cancer research applications.Formule :C23H26ClN3O5Couleur et forme :SolidMasse moléculaire :459.923Cimpuciclib tosylate
CAS :Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.Formule :C37H43FN8O4SCouleur et forme :SolidMasse moléculaire :714.85DB18
CAS :DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].Formule :C24H18ClN7O3Couleur et forme :SolidMasse moléculaire :487.9CDK1-IN-7
CAS :CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.Formule :C23H19ClN4O3Couleur et forme :SolidMasse moléculaire :434.88PPA-037
CAS :PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.Formule :C25H27N7Couleur et forme :SolidMasse moléculaire :425.53CDK5-IN-2
CAS :CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Formule :C29H28FN5OCouleur et forme :SolidMasse moléculaire :481.56CDK1-IN-5
CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.Formule :C27H26ClN5OSCouleur et forme :SolidMasse moléculaire :504.05Protein kinase inhibitor 13
CAS :Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Formule :C19H20FN5OSCouleur et forme :SolidMasse moléculaire :385.458CDK9/PARP-IN-1
CAS :CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.Formule :C38H34F2N8O3Couleur et forme :SolidMasse moléculaire :688.725YKL-1-116
CAS :YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.Formule :C34H38N8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :606.72Protein Kinase Inhibitor 12
CAS :Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.Formule :C14H14N4OSDegré de pureté :98.06%Couleur et forme :SolidMasse moléculaire :286.35Anticancer agent 30
Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.Formule :C22H15ClFNOCouleur et forme :SolidMasse moléculaire :363.81p38α inhibitor 9
CAS :p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.Formule :C27H24FN3O3Couleur et forme :SolidMasse moléculaire :457.496CDK2-IN-8
CDK2-IN-8 is a potent CDK2 inhibitor (IC50= 1.74 μM). CDK2-IN-8 exhibits antiproliferative activity. CDK2-IN-8 can be used for the research of melanoma.Formule :C22H25N5O3Couleur et forme :SolidMasse moléculaire :407.47CDK2-IN-30
CAS :CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.Formule :C18H25N7O3SCouleur et forme :SolidMasse moléculaire :419.50CDK7-IN-18
CAS :CDK7-IN-18 (Compound 15) is a pyrimidine-derived CDK7 inhibitor suitable for studying cancers with transcriptional dysregulation.Formule :C22H24F3N7OSDegré de pureté :99.28% - 99.54%Couleur et forme :SolidMasse moléculaire :491.53CDK2/4-IN-2
CAS :CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.Formule :C18H20F3N7O3S2Couleur et forme :SolidMasse moléculaire :503.52CDK7-IN-26
CAS :CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor with an IC50 of 7.4 nM. The compound effectively suppresses the growth of xenograft tumors derived from triple-negative breast cancer (TNBC) cell lines in vivo and has an IC50 of 0.15 μM for inhibiting MDA-MB-453 cells in vitro.Formule :C22H22FN6OPSMasse moléculaire :468.49CDK4/6-IN-3
CAS :CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.Formule :C25H31FN8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :462.57CDK8-IN-14
CAS :CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].Formule :C18H13N3O2Couleur et forme :SolidMasse moléculaire :303.31DDO-6079
CAS :DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.Formule :C18H13ClN2O3Couleur et forme :SolidMasse moléculaire :340.76GFB-12811
CAS :GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Formule :C22H23F4N5ODegré de pureté :98.88%Couleur et forme :SolidMasse moléculaire :449.44LY3143921 hydrate
CAS :LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Formule :C16H14FN5O2Degré de pureté :98.43%Couleur et forme :SolidMasse moléculaire :327.31Tanuxiciclib
CAS :Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Formule :C15H13FN6OCouleur et forme :SolidMasse moléculaire :312.308GSK-3/CDK5/CDK2-IN-1
CAS :GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.433Tibremciclib
CAS :Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
Formule :C28H32F2N8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :518.6YK-2168
CAS :YK-2168 is a differentiated selective inhibitor of CDK9.
Formule :C16H18ClN5Couleur et forme :SolidMasse moléculaire :315.80
